Latest News

Abexinostat Significantly Reversed Treatment Resistance in GSK’s Pazopanib- and other VEGF inhibitor-refractory Tumors in a 51-Patients Ph 1b Trail Led by Professor Munster at UCSF
Image 03/17/2017 news admin

https://www.ncbi.nlm.nih.gov/pubmed/28221861 Abstract Purpose This phase I trial evaluated epigenetic modulation of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor by using a histone deacetylase abexinostat in combination with pazopanib to enhance response and reverse resistance. Patients and Methods Pazopanib was administered once a day on days 1 to 28 and abexinostat was administered orally twice
Details

Xynomic Pharma has acquired Greater China rights to a novel ACAT-1 inhibitor for cancer indications
Image 03/11/2017 news admin

March. 8, 2017 — Xynomic Pharmaceuticals, Inc., a US-China oncology startup, has acquired Greater China rights to a novel ACAT-1 inhibitor for cancer indications from Resarci Therapeutics of West Lafayette, Indiana. It will be tested as a treatment for prostate, pancreatic and other solid tumors. Xynomic will pay $1.2 million in upfront and milestone payments,
Details

Xynomic Pharma Has Acquired Worldwide Rights of Abexinostat
Image 02/25/2017 news admin

CHEYENNE, Wyoming, Feb. 24, 2017 /PRNewswire/ — Xynomic Pharmaceuticals, Inc., an oncology drug research and development company, today announced that it has acquired exclusive worldwide rights to develop, manufacture and commercialize Abexinostat, a potentially best-in-class innovative HDAC inhibitor targeting hematological and solid tumors. To date a total of 17 Phase 1 and 2 clinical trials
Details